J&J Contests FDA-Proposed Cap With Study Championing High SPF Sunscreens
This article was originally published in The Rose Sheet
Executive Summary
Johnson & Johnson is strengthening its stance against FDA's proposed maximum for sun protection factors on sunscreen products with a new study refuting the notion that high SPF formulas cannot be accurately and consistently measured.
You may also be interested in...
FDA Considers Capping SPF Values At 50+ Despite Efficacy Data
FDA might cap sun-protection factors at 50 or 50+ so as not to mislead consumers about the clinical benefit of sunscreens with higher SPF values, according to a proposed rule.
FDA Considers Capping SPF Values At 50+ Despite Efficacy Data
FDA might cap sun-protection factors at 50 or 50+ so as not to mislead consumers about the clinical benefit of sunscreens with higher SPF values, according to a proposed rule.
Sunscreen Rule Will Cost Four Times What FDA Predicted, Industry Tells OMB
FDA's low-ball estimate of costs its final OTC sunscreen monograph will impose on industry - a quarter of the amount anticipated by manufacturers - relieved the agency from having to submit a full account of its rulemaking to the Office of Management and Budget, Energizer Holdings suggests